Genetic variants that affect activity of the HPA axis are present in women who experience postpartum depression, suggesting the possibility that a diagnostic test could be developed.
Postpartum depression is a specific subcategory of depression with a distinct genetic element.
Women who develop postpartum depression were more likely to have gene variants that control activity of the hypothalamic-pituitary-adrenal (HPA) axis.
A simple blood test soon may be able to predict which new mothers will suffer from
postpartum depression, a condition that affects approximately 1 in every 7 women who give birth.
Investigators from the University of Warwick, United Kingdom, identified specific gene variants in women with postpartum depression. Their findings indicate that postpartum depression is a “specific subgroup of depression with a distinct genetic element,” meaning that some women are genetically more prone to react to depression-related environmental triggers. Although current tools can screen for postpartum depression after it has occurred, these findings, according to the authors, would provide an opportunity to identify women at highest risk before the condition appears.
Presenting their research at the joint 15th International Congress of Endocrinology/14th European Congress of Endocrinology in Florence, Italy (May 5-9, 2012), the investigators assessed 200 pregnant women for postpartum depression using the Edinburgh Postnatal Depression Score, once during their first visit to an antenatal clinic and again 2 to 8 weeks after they gave birth.
They found that the women who developed postpartum depression were more likely to have gene variants of the glucocorticoid receptor gene and the corticotrophin-releasing hormone receptor-1 gene, both of which control the activity of the HPA axis.
Although experts already knew an association existed between the HPA axis and depression, this study demonstrates a link between specific elements of this pathway and a specific type of depression, which could eventually allow early identification and treatment of the disorder, the authors suggest.
Read other articles in this issue of Special Delivery
Inactivated COVID-19 vaccines in pregnancy: No impact on neonatal outcome, study finds
November 28th 2023A comprehensive cohort study explored the impact of inactivated COVID-19 vaccines administered within 3 months before conception, revealing reassuring findings that neonatal outcomes, including preterm birth and NICU admission, remain unaffected.
Read More
A closer look at women's concerns on breast density in clinician discussions
November 27th 2023A study found variations in discussions about breast density based on race and ethnicity, leading researchers to urge enhanced cultural competency and shared decision-making to bridge critical gaps in breast density conversations.
Read More
High rates of perinatal anxiety in women from low- and middle-income countries
November 24th 2023A recent comprehensive study reveals that 1 in 5 women in low- and middle-income countries grapple with perinatal anxiety disorders, shedding light on a critical yet often overlooked mental health challenge affecting maternal and infant outcomes in these regions.
Read More